Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
Mayo Clinic in Arizona · Mayo Clinic in Florida · +19 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
721
total citations
- FWCI
- 23.23
- Percentile
- 100%
- References
- 32
Citations per year
Authors
160Topics & keywords
Topics
Keywords
- Multiple myeloma
- Bortezomib
- Medicine
- Internal medicine
- Oncology
- Lenalidomide
- Multicenter study
- Randomized controlled trial
No related works found for this paper.